2-Aryl hydrazonopropanal pharmacophores as potent cytotoxic agents against human hepatocellular carcinoma cell line

  • Khadijah M. AlzaydiEmail author
  • Tamer S. Saleh
Original Research


The versatile synthon E-methyl 2-(2-(1,3-dioxo-1-arylpropan-2-ylidene) hydrazinyl) benzoate has a potent cytotoxic activity, which was screened in vitro for anticancer activity against human hepatocellular carcinoma cell (HCC) line. The results show a higher anticancer efficacy and higher selectivity index (SI) on HCC versus doxorubicin that warrants further studies in both animals and humans; this work has been patented.


Hepatocellular carcinoma 2-Aryl hydrazonopropanals Hydrazonopropanal derivative Doxorubicin Selectivity index (SI) 



This project was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant No. (P-0140-363-0436). The authors, therefore, acknowledged with thanks DSR technical and financial support.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. Akamatsu M (2011) Importance of physicochemical properties for the design of new pesticides. J Agric Food Chem 59:2909–2917CrossRefGoogle Scholar
  2. Alves RC, Alves D, Guz B et al. (2011) Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 10:21–27CrossRefGoogle Scholar
  3. Al-Zaydi KM, Borik RM (2007) Microwave assisted condensation reactions of 2-aryl hydrazonopropanals with nucleophilic reagents and dimethyl acetylenedicarboxylate. Molecules 12:2061–2079CrossRefGoogle Scholar
  4. Al-Zaydi KM, Saleh TS, Bin Hadda T (2019) Potent cytotoxic agents against human hepatocellular carcinoma cell line based 2-aryl hydrazonopropanals pharmacophore. US Patent 10,280, 134B1Google Scholar
  5. Arnott JA, Kumar R, Planey SL (2013) Lipophilicity indices for drug Development. J Appl Biopharm Pharcokin 1:31–36Google Scholar
  6. Arnott JA, Planey SL (2012) The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov 7:863–875CrossRefGoogle Scholar
  7. Badisa RB, Darling-Reed SF, Joseph P, Cooperwood JS, Latinwo LM (2009) Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF7 cells. Anticancer Res 29:2993–2996PubMedPubMedCentralGoogle Scholar
  8. Bassyouni FA, Abu-Baker SM, Mahmoud K, Moharam M, El-Nakkady SS, Abdel-Rehim M (2014) Synthesis and biological evaluation of some new triazolo[1,5-a]quinoline derivatives as anticancer and antimicrobial agents. RSC Adv 4(46):24131–24141CrossRefGoogle Scholar
  9. Blum HE (2005) Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 11:7391–7400PubMedPubMedCentralGoogle Scholar
  10. Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 27:5–16CrossRefGoogle Scholar
  11. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631–651CrossRefGoogle Scholar
  12. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, Cheng AL (2011) Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharm Exp Ther 337:155–161CrossRefGoogle Scholar
  13. Curatolo W (1998) Physical chemical properties of oral drug candidates in the discovery and exploratory drug development settings. Pharm Sci Technol Today 19:387–393CrossRefGoogle Scholar
  14. El-Menshawi BS, Fayad W, Mahmoud K, El-Hallouty SM, El- Manawaty M, Olofsson MH, Linder S (2010) Screening of natural products for therapeutic activity against solid tumors. Indian J Exp Biol 48:258–264PubMedGoogle Scholar
  15. Gleeson MP (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 51:817–834CrossRefGoogle Scholar
  16. Hung CS, Lin SF, Liu HH et al. (2012) Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma. Ann Surg Oncol 19:2744–2752CrossRefGoogle Scholar
  17. Kaseb AO, Shindoh J, Patt YZ et al. (2013) Modified cisplatin/interferon alpha-2b/doxorubicin/5-fluorouracil [PIAF] chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unrespectable hepatocellular carcinoma. Cancer 119:3334–3342CrossRefGoogle Scholar
  18. Kearns EH, Di L (2008) Drug-like properties: concepts, structure design and methods. Elsevier, USAGoogle Scholar
  19. Kellen JA (1993) The reversal of multidrug resistance in cancer (review). Anticancer Res 13:959–961PubMedGoogle Scholar
  20. Kodama Y, Fumoto S, Nishi J et al. (2008) Absorption and distribution characteristics of 5-fluorouracil [5-FU] after an application to the liver surface in rats in order to reduce systemic side effects. Biol Pharm Bull 31:1049–1052CrossRefGoogle Scholar
  21. Li T, Dong ZR, Guo ZY et al. (2013) Aspirin enhances IFN-alpha-induced growth inhibition and apoptosis of hepatocellular carcinoma via JAK1/STAT1 pathway. Cancer Gene Ther 20:366–374CrossRefGoogle Scholar
  22. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 46:3–26CrossRefGoogle Scholar
  23. Malik MA, Raza MK, Dar OA, Abid M, Wani MY, Al-Bogami AS, Hashmi AA (2019) Probing the antibacterial and anticancer potential of tryptamine based mixed ligand Schiff base Ruthenium (III) complexes. Bioorg Chem 87:773–782CrossRefGoogle Scholar
  24. Masriani M, Mustofa M, Jumina J, Sunarti S, Enawaty E (2014) Cytotoxic and pro-apoptotic activities of crude alkaloid from root of sengkubak (Pynarrhena cauliflora (Miers) Diels) in human breast cancer T47D cell line. Sch Acad J Biosci 2(5):336–340Google Scholar
  25. Minotti G, Recalcati S, Mordente A et al. (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 12:541–552CrossRefGoogle Scholar
  26. Miyamoto Y, Koh YH, Park YS et al. (2003) Oxidative stress caused by inactivation of glutathione peroxidase and adaptive responses. Biol Chem 384:567–574CrossRefGoogle Scholar
  27. Mosmann T (1983) Rapid colorimetric assays for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63CrossRefGoogle Scholar
  28. Rutman RJ, Cantarow A, Paschkis KE (1954) Studies in 2-acetylaminofluorene carcinogenesis. I. The intracellular distribution of nucleic acids and protein in rat liver. Cancer Res 14:111–114PubMedGoogle Scholar
  29. Song DS, Bae SH, Song MJ et al. (2013) Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 19:4679–4688CrossRefGoogle Scholar
  30. Tapiero H, Mishal Z, Wioland M, Silber A, Fourcade A, Zwingelstein G (1986) Changes in biophysical parameters and in phospholipid composition associated with resistance to doxorubicin. Anticancer Res 6:649–652PubMedGoogle Scholar
  31. Thabrew MI, Hughes RD, McFarlane IG (1997) Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharm 49:1132–1135CrossRefGoogle Scholar
  32. Trott O, Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455–461PubMedPubMedCentralGoogle Scholar
  33. Wang S, Kotamraju S, Konorev E et al. (2002) Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J 367:729–740CrossRefGoogle Scholar
  34. Wani MY, Bhat AR, Azam A, Athar F (2013) Nitroimidazolyl hydrazones are better amoebicides than their cyclized 1, 3, 4-oxadiazoline analogues: in vitro studies and Lipophilic efficiency analysis. Eur J Med Chem 64:190–199CrossRefGoogle Scholar
  35. Whittaker S, Marais R, Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29:4989–5005CrossRefGoogle Scholar
  36. Yang TS, Lin YC, Chen JS et al. (2014) Phase II study of gemcitabine Oncol Rev 8:246, 31Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Chemistry Department, Faculty of ScienceUniversity of JeddahJeddahSaudi Arabia
  2. 2.Department of Chemistry, Faculty of Science, Al-Faisaliah CampusKing Abdulaziz UniversityJeddahSaudi Arabia
  3. 3.Green Chemistry DepartmentNational Research CentreCairoEgypt

Personalised recommendations